

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) ~~The PTPRK_{Gly677}Arg682~~ An isolated immunogenic peptide consisting of the amino acid sequence of SEQ ID NO: 1.
2. (currently amended) A monoclonal or polyclonal antibody, or an active fragment thereof, which selectively binds the isolated peptide of claim 1.
3. (currently amended) An isolated nucleic acid molecule encoding the isolated peptide of claim 1.
4. (original) An expression vector carrying the nucleic acid molecule of claim 3.
5. (original) A host cell containing the vector of claim 4.
6. (currently amended) An isolated CD4+ T lymphocyte able to selectively recognize and bind ~~the~~ an isolated peptide consisting of the amino acid sequence of SEQ ID NO: 1 associated to a HLA-Class II molecule.

7.(original) A T lymphocyte according to claim 6, which selectively recognizes and binds a peptide/HLA-DR β 1*1001 complex.

8. (previously presented) Antigen presenting cells carrying the peptide SEQ ID NO: 1 bound to a HLA-DR β 1*1001 molecule.

9. (currently amended) ~~Pharmaceutical~~ An immunogenic composition, comprising: containing the peptide an immunogenic peptide consisting of the amino acid sequence of SEQ ID NO: 1 or a nucleic acid molecule encoding [[it]] said immunogenic peptide, in admixture with ~~pharmaceutically acceptable~~ excipients.

10. (canceled)

11.(currently amended) A medicament ~~for the preventive or therapeutic treatment of cancer~~ comprising ~~one of peptide SEQ ID NO: 1~~ an immunogenic peptide consisting of the amino acid sequence of SEQ ID NO: 1, and nucleic acid molecules encoding ~~[[it]]~~ said immunogenic peptide.

12.(canceled)

13. (currently amended) A diagnostic composition comprising ~~peptide SEQ ID NO: 1~~ an immunogenic peptide consisting of the

amino acid sequence of SEQ ID NO: 1, or of a nucleic acid molecule encoding [[it]] said immunogenic peptide.

14. (canceled)